Výsledky vyhledávání - "Kjell Magne, Tveit"

Clinicopathological factors associated with tumour‐specific mutation detection in plasma of patients with RAS ‐mutated or BRAF ‐mutated metastatic colorectal cancer

Autor: Olav Dajani, Elin H. Kure, Per Pfeiffer, Bengt Glimelius, K. L.G. Spindler, Halfdan Sorbye, Ole Christian Lingjærde, Niels Pallisgaard, Tormod Kyrre Guren, Julian Hamfjord, Kjell Magne Tveit

Publikováno v: International Journal of Cancer. 149:1385-1397

Detection of tumour-specific circulating cell-free DNA in plasma (ctDNA) fails in a significant number of cases depending on the clinical context. The primary aim was to investigate clinicopathological factors associated with detection of ctDNA in pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::542b285a746a26da02c56a6243657e3a
https://doi.org/10.1002/ijc.33672

Zobrazit plný text záznamu

Autor: Tor Magnus Smedman, Tormod Kyrre Guren, Kjell Magne Tveit, Maria Thomsen, Marit Helen Andersen, Pål-Dag Line, Svein Dueland

Publikováno v: Transplant International. 35

Liver transplantation (LT) for patients with non-resectable colorectal liver metastases (CRLM) offers improved survival and has gained increased interest internationally the last years. The aim of this study was to describe the health-related quality

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e69662fefd9a78ea627d2cde81a72755
https://doi.org/10.3389/ti.2022.10404

Zobrazit plný text záznamu

Survival Trends of Right- and Left-Sided Colon Cancer across Four Decades : A Norwegian Population-Based Study

Autor: Tor Åge Myklebust, Tormod Kyrre Guren, Elin H. Kure, Inger Kristin Larsen, Bengt Glimelius, Kjell Magne Tveit, Julian Hamfjord, Marianne Grønlie Guren

Publikováno v: Cancer Epidemiology, Biomarkers and Prevention

Background: Patients with right-sided colon cancer (RCC) and left-sided colon cancer (LCC) differ clinically and molecularly. The main objective was to investigate stage-stratified survival and recurrence of RCC and LCC across four 10-year periods. M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fbffa9959ad02387b24f0f6c9ba0e65
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-469211

Zobrazit plný text záznamu

Treatment breaks in first line treatment of advanced colorectal cancer: An individual patient data meta-analysis

Autor: Kaitlyn K.H. Goey, Harpreet Wasan, Aimery de Gramont, Benoist Chibaudel, Tim Maughan, Axel Hinke, Roberto Labianca, Cornelis J A Punt, Kjell Magne Tveit, Susanna Hegewisch-Becker, Louise J. Brown, David E. Fisher, Richard Kaplan, Richard Adams, Eduardo Diaz Rubio, Dirk Arnold, Miriam Koopman

Publikováno v: Cancer treatment reviews. 99

Background\ud Intermittent systemic anti-cancer therapy in patients with advanced colorectal cancer (aCRC) may improve quality of life without compromising overall survival (OS). We aimed to use individual patient data meta-analysis (IPDMA) from mult

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64d0a39b4f5afcf94ef0cb267f0ef019
http://www.scopus.com/inward/record.url?scp=85107814950&partnerID=8YFLogxK

Zobrazit plný text záznamu

Akademický článek

Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.

Autor: Line S Tarpgaard, Tormod K Guren, Bengt Glimelius, Ib J Christensen, Per Pfeiffer, Elin H Kure, Halfdan Sorbye, Tone Ikdahl, Mette Yilmaz, Julia S Johansen, Kjell Magne Tveit

Publikováno v: PLoS ONE, Vol 9, Iss 2, p e87746 (2014)

We aim to test the hypothesis that high plasma YKL-40 is associated with short progression-free survival (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated with first-line oxaliplatin and 5-flourouracil with

Externí odkaz: https://doaj.org/article/5220fea8fbdf4802a9079ec55874bed7

Zobrazit plný text záznamu

Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS-mutated or BRAF-mutated metastatic colorectal cancer

Autor: Julian, Hamfjord, Tormod Kyrre, Guren, Bengt, Glimelius, Halfdan, Sorbye, Per, Pfeiffer, Olav, Dajani, Ole Christian, Lingjaerde, Kjell Magne, Tveit, Niels, Pallisgaard, Karen-Lise Garm, Spindler, Elin H, Kure

Publikováno v: International journal of cancerREFERENCES. 149(6)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3e1dd90ab061b9525b2e3b0858df5912
https://pubmed.ncbi.nlm.nih.gov/33961700

Zobrazit plný text záznamu

Equitable access to cancer patient pathways in Norway – a national registry-based study

Autor: Lise Balteskard, Ivar Heuch, Kjell Magne Tveit, Bjarne K. Jacobsen, Frank Olsen

Publikováno v: BMC Health Services Research
BMC Health Services Research, Vol 21, Iss 1, Pp 1-13 (2021)

Background In 2015, cancer patient pathways (CPP) were implemented in Norway to reduce unnecessary non-medical delay in the diagnostic process and start of treatment. The main aim of this study was to investigate the equality in access to CPPs for pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::920efb87259b3ef13afca2d9b5008957
https://hdl.handle.net/11250/2936423

Zobrazit plný text záznamu

Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study

Autor: Maria Thomsen, Per Pfeiffer, Fridbjorn Sigurdsson, Inger Marie Bowitz Lothe, Bengt Glimelius, Pia Österlund, Kjell Magne Tveit, Eva Skovlund, Elin H. Kure, Halfdan Sorbye, Tormod Kyrre Guren, Thoralf Christoffersen, Astrid M. Dalsgaard

Publikováno v: British Journal of Cancer
Guren, T K, Thomsen, M M, Kure, E H, Sorbye, H, Glimelius, B, Pfeiffer, P, Österlund, P, Sigurdsson, F, Lothe, I M B, Dalsgaard, A M, Skovlund, E, Christoffersen, T & Tveit, K M 2017, ' Cetuximab in treatment of metastatic colorectal cancer : final survival analyses and extended RAS data from the NORDIC-VII study ', British Journal of Cancer, vol. 116, no. 10, pp. 1271-1278 . https://doi.org/10.1038/bjc.2017.93

BACKGROUND: The NORDIC-VII study is a randomised phase III trial of cetuximab plus continuous or intermittent fluorouracil, folinic acid, and oxaliplatin (Nordic FLOX) vs FLOX alone in first-line treatment of metastatic colorectal cancer. The present

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee4167376ac87d2e8d8719d29d555e86
https://doi.org/10.1038/bjc.2017.93

Zobrazit plný text záznamu

Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy

Autor: Elin H. Kure, Halfdan Sorbye, Kjell Magne Tveit, Niels Pallisgaard, Olav Dajani, K. L.G. Spindler, Ole Christian Lingjærde, Julian Hamfjord, Tormod Kyrre Guren, Per Pfeiffer, Bengt Glimelius, Julia S. Johansen

Publikováno v: Hamfjord, J, Guren, T K, Dajani, O, Johansen, J S, Glimelius, B, Sorbye, H, Pfeiffer, P, Lingjærde, O C, Tveit, K M, Kure, E H, Pallisgaard, N & Spindler, K-L G 2019, ' Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy ', Annals of Oncology, vol. 30, no. 7, pp. 1088-1095 . https://doi.org/10.1093/annonc/mdz139
Annals of Oncology
Hamfjord, J, Guren, T K, Dajani, O, Johansen, J S, Glimelius, B, Sorbye, H, Pfeiffer, P, Lingjærde, O C, Tveit, K M, Kure, E H, Pallisgaard, N & Spindler, K L G 2019, ' Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy ', Annals of Oncology, vol. 30, no. 7, mdz139, pp. 1088-1095 . https://doi.org/10.1093/annonc/mdz139

BACKGROUND: Metastatic colorectal cancer (mCRC) is a heterogeneous disease where prognosis is dependent both on tumor biology and host factors. Total circulating cell-free DNA (cfDNA) has shown to harbor prognostic information in mCRC, although less

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::360d1d22c619f922ee55d965bc432fc4
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-394653

Zobrazit plný text záznamu

Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer

Autor: Christian Kersten, Julia S. Johansen, Thoralf Christoffersen, Tormod Kyrre Guren, Kjell Magne Tveit, Tone Ikdahl, Maria Thomsen, Elin H. Kure, Eva Skovlund, Halfdan Sorbye, Per Pfeiffer, Bengt Glimelius

Publikováno v: Oncotarget
Thomsen, M, Kersten, C, Sorbye, H, Skovlund, E, Glimelius, B, Pfeiffer, P, Johansen, J S, Kure, E H, Ikdahl, T, Tveit, K M, Christoffersen, T & Guren, T K 2016, ' Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer ', Oncotarget, vol. 7, no. 46, pp. 75013-75022 . https://doi.org/10.18632/oncotarget.12601
Thomsen, M, Kersten, C, Sorbye, H, Skovlund, E, Glimelius, B, Pfeiffer, P, Johansen, J S, Kure, E H, Ikdahl, T, Tveit, K M, Christoffersen, T & Guren, T K 2016, ' Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer ', OncoTarget, vol. 7, no. 46, pp. 75013-75022 . https://doi.org/10.18632/oncotarget.12601

// Maria Thomsen 1, 2 , Christian Kersten 3 , Halfdan Sorbye 4 , Eva Skovlund 5 , Bengt Glimelius 6 , Per Pfeiffer 7 , Julia S. Johansen 8 , Elin H. Kure 9 , Tone Ikdahl 10 , Kjell Magne Tveit 1, 2, 11 , Thoralf Christoffersen 12 , Tormod Kyrre Guren

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13660df0705d1fc166d38b27ae047df3
http://europepmc.org/articles/PMC5342719

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání